JP2010535504A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535504A5
JP2010535504A5 JP2010519930A JP2010519930A JP2010535504A5 JP 2010535504 A5 JP2010535504 A5 JP 2010535504A5 JP 2010519930 A JP2010519930 A JP 2010519930A JP 2010519930 A JP2010519930 A JP 2010519930A JP 2010535504 A5 JP2010535504 A5 JP 2010535504A5
Authority
JP
Japan
Prior art keywords
fragment
composition
polypeptide
seq
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010519930A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535504A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/009282 external-priority patent/WO2009020553A2/en
Publication of JP2010535504A publication Critical patent/JP2010535504A/ja
Publication of JP2010535504A5 publication Critical patent/JP2010535504A5/ja
Pending legal-status Critical Current

Links

JP2010519930A 2007-08-03 2008-08-01 クラミジア抗原 Pending JP2010535504A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96321507P 2007-08-03 2007-08-03
PCT/US2008/009282 WO2009020553A2 (en) 2007-08-03 2008-08-01 Chlamydia antigens

Publications (2)

Publication Number Publication Date
JP2010535504A JP2010535504A (ja) 2010-11-25
JP2010535504A5 true JP2010535504A5 (enExample) 2012-10-11

Family

ID=40341938

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010519930A Pending JP2010535504A (ja) 2007-08-03 2008-08-01 クラミジア抗原

Country Status (7)

Country Link
US (1) US20100260791A1 (enExample)
EP (1) EP2185577A4 (enExample)
JP (1) JP2010535504A (enExample)
CN (1) CN102027003A (enExample)
AU (1) AU2008284352A1 (enExample)
CA (1) CA2695421A1 (enExample)
WO (1) WO2009020553A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981905B1 (en) * 2006-01-16 2016-08-31 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Chlamydia vaccine
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
US8313894B2 (en) 2008-07-01 2012-11-20 Genocea Biosciences, Inc. Antigen screening system
AU2012253359B2 (en) 2011-05-11 2017-06-08 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
TR201809679T4 (tr) * 2012-12-28 2018-07-23 Cellestis Ltd Hücre aracılı bir immün yanıt tahlili.
AU2018240199A1 (en) 2017-03-20 2019-10-17 Genocea Biosciences, Inc. Treatment methods
EP3651794A1 (en) * 2017-07-13 2020-05-20 Nanobio Corporation Chlamydia nanoemulsion vaccine

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
DE69535905D1 (de) 1994-07-15 2009-02-26 Coley Pharm Group Inc Immunomodulatorische Oligonukleotide
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US7041490B1 (en) * 1997-11-28 2006-05-09 Serono Genetics Institute, S.A. Chlamydia trachomatis polynucleotides and vectors, recombinant host cells, DNA chips or kits containing the same
CN1280619A (zh) * 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
US6822071B1 (en) * 1998-11-12 2004-11-23 The Regents Of The University Of California Polypeptides from Chlamydia pneumoniae and their use in the diagnosis, prevention and treatment of disease
US20020061848A1 (en) * 2000-07-20 2002-05-23 Ajay Bhatia Compounds and methods for treatment and diagnosis of chlamydial infection
US6565856B1 (en) * 1998-12-08 2003-05-20 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
DE60228758D1 (de) * 2001-12-12 2008-10-16 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia tracheomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
WO2005002619A2 (en) * 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
US8481057B2 (en) * 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
US20100310593A1 (en) * 2007-06-14 2010-12-09 Emergent Product Development Gaithersburg Inc. Vaccines Against Chlamydia Infection

Similar Documents

Publication Publication Date Title
CN116096735A (zh) 乙型冠状病毒的预防和治疗
CN110862435A (zh) 非洲猪瘟ctl表位多肽及其应用
JP2003529319A (ja) HIV−1gp41を標的化する広範に中和する抗体を誘発する方法
JP2010535504A5 (enExample)
JP6676661B2 (ja) ブタ生殖器呼吸器症候群及びブタサーコウイルス関連疾患に対するワクチン組成物
JP7146926B2 (ja) Cd4ヘルパーt細胞エピトープの融合ペプチドおよびそのワクチン
TWI741241B (zh) 用於治療及/或預防異位性皮膚炎之il-31胜肽免疫原及其劑型
US20220073946A1 (en) Virus-like particles of cmv modified by fusion
WO2022127825A1 (zh) 针对新型冠状病毒感染的疫苗组合物
KR20150131292A (ko) 인플루엔자 핵단백질 백신
CN102000329B (zh) 一种改造的非致病细菌来源的鞭毛素粘膜佐剂及制备方法
WO2016178811A1 (en) Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
Lu et al. DNA vaccine ROP 29 from Toxoplasma gondii containing R848 enhances protective immunity in mice
JP2021524280A (ja) ハウスダストダニアレルギーの処置および予防
KR20180038557A (ko) 타겟 폴리펩티드를 제시하기 위한 폴리펩티드 캐리어 및 이의 용도
JP2017527293A5 (enExample)
KR101881947B1 (ko) 기생충 질병에 대한 백신 또는 진단용으로 사용되는 l3 및/또는 l5 공급원의 용도
Li et al. Enhancement of humoral immune responses to HBsAg by heat shock protein gp96 and its N-terminal fragment in mice
CN118871587A (zh) 截短的水痘-带状疱疹病毒囊膜糖蛋白gE
WO2019228032A1 (zh) 磷酸化多肽抗原疫苗及其制备方法和应用
Shen et al. DNA vaccine prime and replicating vaccinia vaccine boost induce robust humoral and cellular immune responses against MERS-CoV in mice
CN105198982B (zh) 基于il-6的抗原表位及其应用
CN109748952B (zh) 辅助性表位肽及其应用
KR20240163165A (ko) 에피토프의 조합과 그의 용도, 백신 구조물, 면역 반응의 유도 방법 에피토프의 식별 방법
CN115850398A (zh) 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用